WHY I (ALMOST) NEVER BOLUS 5-FLUOROURACIL I've been pondering this thread for a while but it's become more urgent in light of another looming chemo shortage <deep sigh>, this time with an imminent dearth of THE foundational drug of GI oncology: 5-fluorouracil, or 5-FU

Bravo to ASCO for providing these patient-facing synopses of major trials presented at #ASCO24 This is truly respectful of our partners in dialogue and the ULTIMATE stakeholders in meaningful progress society.asco.org/practice-patie…

Initial thoughts I will bring back to clinic from LAURA and ADRIATIC from #ASCO24 #lcsm

🔥ABC-07🔥 Update ⚠️Gem-Cis➡️SBRT for locally advanced, unresectable, cholangiocarcinoma did not improve PFS or OS 🔎 Suggestion of improved 1- and 2- year OS (43% vs 32%) ⬆️Systemic control needed to select pts/enhance role of ☢️❓ Perhaps in the Gem-Cis- ICI era❓ #ASCO24

BREAKING: The FDA Approves Imetelstat in Lower-Risk MDS With Transfusion-Dependent Anemia targetedonc.com/view/fda-oks-i…

1/🧵 Why I'm skeptical about Imetelstat's use for MDS treatment: Imetelstat is an oligonucleotide that inhibits telomerase activity by binding to the RNA template of telomerase.1/12

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.10…

“All of these projects are innovative, cutting edge and address major unmet needs in blood-based malignancies." A $5M grant from The Leukemia & Lymphoma Society supports research into new immunotherapies for various blood cancers, including personalized cancer vaccines. bit.ly/4bMkvsa

ProTip: That is not why they do prior authorizations….

Outcomes for Hodgkin improving all the time. BUT: - older pts still do relatively poorly - overtreating many pts to improve cure for some - cumulative anthracycline exposure still a problem - acute tox still a burden including prolonged fatigue More work to do!

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial - Suo - 2024 - Hematological Oncology - Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10… #leusm #AML

The most dangerous grift in ophthalmology right now is “glasses are harmful.” People that claim diet, exercise, and a 10 part instructional webinar can help you live spectacle free! No. Stop it. It’s not a big deal for most adults. They will lose some money before realizing

👉👉👉Delighted to share review article on #CLL (with my colleagues Drs Bill Wierda and Susan O’Brien) published in the Journal Lancet today!! The Lancet Bill Wierda, MD, PhD MD Anderson Cancer Center Hagop Kantarjian,MD Chronic lymphocytic leukaemia - The Lancet thelancet.com/journals/lance…

T-cell engager therapy for lymphoma! This free and very comprehensive review from Blood Advances on CART and bispecifics in lymphoma is quite literally amazing. Very concise but has all the details I want and need. Time to memorize this table! tinyurl.com/43jjpraz

Vorasidenib now FDA Oncology approved based off Ph3 #INDIGO for residual/recurrent Gr 2 Astrocytoma/Oligodendroglioma w/ IDH1/2 mutation! -mPFS, 27.7mos vs. 11.1mos (HR: 0.39) - Time to next intervention was significantly improved - Gr ≥ 3 AEs 22.8% #OncTwitter #NeuroOnc

Had the opportunity to attempt to “demystify” the fellowship application process with Marc Braunstein, MD, PhD, FACP and chadi nabhan MD, MBA, FACP on the Healthcare Unfiltered podcast. A great listen for those applying/planning to apply fellowship! podcasts.apple.com/us/podcast/hea…

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

2024 ELN AML risk treated with low intensity therapies Good! NPM1 or IDH1 or IDH2 or DDX41 mutated plus FLT3/NRAS/KRAS/TP53 wildtype Intermediate: FLT3 or NRAS or KRAS mutated plus TP53 wildtype Adverse: TP53 mutated ashpublications.org/blood/article/…

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… very important analysis!!! #lymsm

Check out our latest paper in Journal of Clinical Oncology on surrogacy of endpoints in 1L #CLL trials! Led by Florian Simon, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇 ascopubs.org/doi/10.1200/JC…